Effect of Essential Oil on Patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Pilot Randomized Controlled Trial
- PMID: 29948596
- DOI: 10.1007/s11655-018-2797-5
Effect of Essential Oil on Patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Pilot Randomized Controlled Trial
Abstract
Objective: To evaluate the efficacy and safety of essential oil treatment for type III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).
Methods: A randomized controlled trial was conducted from December 2014 to October 2015. Seventy type III CP/CPPS patients were assigned to the essential oil group (35 cases) or almond placebo oil control group (35 cases) by a random number table. The oil was smeared by self-massage on the suprapubic and sacral region once a day for 4 weeks. The National Institutes of Health Chronic Prostatitis Syndrome Index (NIH-CPSI) and expressed prostatic secretions (EPS) were examined. The primary outcome was NIH-CPSI pain domain. The secondary outcomes included other NIH-CPSI domains and laboratory examinations of EPS. Adverse events were also observed.
Results: Sixty-six subjects completed the full 4-week treatment. There was no significant difference between almond oil control and essential oil groups in terms of the total score of NIH-CPSI, pain, quality of life and urination domain scores of NIH-CPSI and EPS examinations (P>0.05). In the essential oil group, pain between rectum and testicles (perineum) in the domain of pain or discomfort was significantly reduced at week 2 and week 4 compared with almond oil control group (P<0.01). No serious adverse events occurred.
Conclusion: The essential oil may reduce the pain or discomfort in the perineum region in patients with CP/CPPS. (Registration No. ChiCTR-IPR-14005448).
Keywords: chronic prostatitis/chronic pelvic pain syndrome; essential oil; randomized controlled trial.
Similar articles
-
Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study.Urology. 2003 Sep;62(3):425-9. doi: 10.1016/s0090-4295(03)00466-7. Urology. 2003. PMID: 12946740 Clinical Trial.
-
Treatment of refractory category III nonbacterial chronic prostatitis/chronic pelvic pain syndrome with intraprostatic injection of onabotulinumtoxinA: a prospective controlled study.Can J Urol. 2018 Apr;25(2):9273-9280. Can J Urol. 2018. PMID: 29680006 Clinical Trial.
-
Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial.J Urol. 2004 Apr;171(4):1594-7. doi: 10.1097/01.ju.0000117811.40279.19. J Urol. 2004. PMID: 15017228 Clinical Trial.
-
Non-pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review.BJU Int. 2019 Aug;124(2):197-208. doi: 10.1111/bju.14492. Epub 2019 Jan 17. BJU Int. 2019. PMID: 30019814
-
The efficacy of antibiotic and alpha-blocker combination therapy versus antibiotic monotherapy in chronic prostatitis/chronic pelvic pain syndrome: A systematic review.Low Urin Tract Symptoms. 2023 Jul;15(4):107-115. doi: 10.1111/luts.12477. Epub 2023 Apr 2. Low Urin Tract Symptoms. 2023. PMID: 37005791
Cited by
-
Efficacy and Safety of Guihuang Formula in Treating Type III Prostatitis Patients with Dampness-Heat and Blood Stasis Syndrome: A Randomized Controlled Trial.Chin J Integr Med. 2022 Oct;28(10):879-884. doi: 10.1007/s11655-022-3467-1. Epub 2022 Apr 13. Chin J Integr Med. 2022. PMID: 35419726 Free PMC article. Clinical Trial.
-
Analgesic Potential of Terpenes Derived from Cannabis sativa.Pharmacol Rev. 2021 Oct;73(4):98-126. doi: 10.1124/pharmrev.120.000046. Pharmacol Rev. 2021. PMID: 34663685 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous